CALLIDITAS THERAPEUTICS AB revenue breakdown overview

CALLIDITAS THERAPEUTICS AB revenue for the last year amounted to 107.92 M EUR, the most of which — 97.24 M EUR — came from its highest performing source at the moment, Therapeutics for Renal Disease Immunoglobulin, the year earlier bringing 33.51 M EUR. The greatest contribution to the revenue figure was made by United States — last year it brought CALLIDITAS THERAPEUTICS AB 96.20 M EUR, and the year before that — 33.22 M EUR.